Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston May 27, 2022 9:54am
129 Views
Post# 34711777

RE:RE:RE:RE:RE:This constant selling...........

RE:RE:RE:RE:RE:This constant selling...........

TLT has identified commercial revenues (projected) starting Jan. 2023.  So I assume they have more info and insights than you.

_____________________

 

RE:RE:RE:RE:This constant selling...........
Ya if we apply Q4 2022 for BTD and that takes 6 months.. then AA takes what 4months. Your basically end of 2023 Thanks but no thanks. That won't fly at the agm A buyout of technologies is very much a reasonable position at this point And we know pharma influences fda in decision making aka the vaccine right. So if a big pharma paid roger u know they Seinfeld the hammer to get It the rest of the way I'm absolutely sick of Thomas the blue trail little east york stories of Roger's baby has to grind it out at .30c Endocyte deal is the pinnacle template for a single asset The range for deals is 2-10b. And I didn't say for all of the IP lol
<< Previous
Bullboard Posts
Next >>